CANY
CRBP icon

Caxton Associates (New York)’s Corbus Pharmaceuticals CRBP Stock Holding History

Caxton Associates (New York)’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,070
Closed -$521K – 348
2020
Q2 		$521K Buy
2,070
+1,371
+196% +$277K 0.05% 131
2020
Q1 		$110K Buy
+699
New +$118K 0.02% 382

Other funds holding CRBP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Caxton Associates (New York)'s CRBP Position: Q3 2020 in Review

Caxton Associates (New York) sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 2,070 shares — an estimated $521K sold.

Caxton Associates (New York) first reported a position in CRBP in Q1 2020 and held it in 2 quarters. The position peaked at $521K in Q2 2020. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

  • Caxton Associates (New York) reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 2,070 Corbus Pharmaceuticals shares in Q3 2020, an estimated $521K.
  • Caxton Associates (New York) first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Corbus Pharmaceuticals position peaked at $521K in Q2 2020.
  • 122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on Caxton Associates (New York)'s 13F filing for Q3 2020, filed 16 Nov 2020.